Biomarkers May Help Predict Risk Of Alzheimer's Disease In Patients With Mild Cognitive Impairment:
"ScienceDaily (July 30, 2009) — Several cerebrospinal fluid (CSF) biomarkers showed good accuracy in identifying patients with mild cognitive impairment who progressed to Alzheimer disease, according to a new study.
. . .
Because of the type of progression of the disease, there is a need for methods enabling early diagnosis. "Treatments would need to be initiated very early in the disease process, before the neurodegenerative process is too severe. Much focus has thus been directed on patients with mild cognitive impairment (MCI), which is a syndrome characterized by cognitive impairment beyond the age-adjusted norm, but not severe enough to fulfill the criteria for dementia," the authors write.
Thursday, July 30, 2009
Biomarkers May Help Predict Risk Of Alzheimer's Disease In Patients With Mild Cognitive Impairment
Subscribe to:
Post Comments (Atom)
Any research that provides additional insight into Alzheimer’s is critical to finding a cure.
ReplyDeleteIt is also important for patients and families affected by Alzheimer’s to consider participating in clinical studies. One such study is the ICARA Study (www.icarastudy.com), whose goal is to explore if an investigational drug, called Bapineuzumab, can help slow the progression of Alzheimer’s Disease. Clinical studies that test new treatments are the best chance we have for fighting this disease.